PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
(Thomson Reuters ONE) -
REGULATED INFORMATION
GHENT, Belgium, 25 November 2013 - Ablynx [Euronext Brussels: ABLX], today
announced, in accordance with Article 14 of the Belgian Law of 2 May 2007
regarding the publication of major shareholdings in issuers whose securities are
admitted to trading on a regulated market (the "Transparency Law"), that it
received a notification of shareholdings from Biotech Value Fund Partners LP
(BVF Partners LP), Biotech Value Fund Inc (BVF Inc) and Sofinnova Partners SAS.
Biotech Value Fund Partners LP and Biotech Value Fund Inc notified that they
have exceeded the 5% threshold and now hold 2,554,524 Ablynx shares, which
represent 5.23% (compared to a 3.49% holding at 30 September 2013) of the
current 48,827,645 outstanding shares of Ablynx.
Sofinnova Partners SAS notified that they have dropped below the 3% threshold
and now have sold their complete stake in Ablynx.
As the general partner of Biotechnology Value Fund LP (BVF) and Biotech Value
Fund II LP (BVF 2), BVF Partners LP (Partners) is authorised to exercise the
voting rights owned directly by BVF and BVF 2. As the advisor to Investment 10,
LLC (INV 10) and the manager of BVF Investments, LLC (BVF LLC) BVF Partners is
authorised to exercise the voting rights owned directly by INV10 and BVF LLC. As
the general partner of BVF Partners, BVF Inc has management authority over BFV
Partners. As the President of BFV Inc, Mr Lampert has management authority over
BFV Inc.
Full versions of all transparency notifications are available on the website of
Ablynx, under the section Investors.
About Ablynx
Ablynx is a biopharmaceutical company engaged in the discovery and development
of Nanobodies(®), a novel class of therapeutic proteins based on single-domain
antibody fragments, for a range of serious human diseases, including
inflammation, haematology, oncology and pulmonary disease. Today, the Company
has approximately 30 programmes in the pipeline and seven Nanobodies at clinical
development stage. Ablynx has on-going research collaborations and significant
partnerships with major pharmaceutical companies including AbbVie, Boehringer
Ingelheim, Eddingpharm, Merck & Co, Merck Serono and Novartis. The Company is
headquartered in Ghent, Belgium.
More information can be found on www.ablynx.com.
For more information, please contact
Ablynx:
Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
+32 (0)473 39 50 68
e: edwin.moses(at)ablynx.com
Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch(at)ablynx.com
Follow us on Twitter (at)AblynxABLX
Ablynx media relations Consilium Strategic Communications:
Mary-Jane Elliott, Amber Bielecka, Lindsey Neville
t: +44 207 920 2345
e: ablynx(at)consilium-comms.com
pdf version of the press release:
http://hugin.info/137912/R/1745629/587503.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Ablynx via GlobeNewswire
[HUG#1745629]
Unternehmensinformation / Kurzprofil:
Datum: 25.11.2013 - 18:00 Uhr
Sprache: Deutsch
News-ID 320137
Anzahl Zeichen: 3927
contact information:
Town:
Ghent/Zwijnaarde
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 157 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")"
steht unter der journalistisch-redaktionellen Verantwortung von
Ablynx (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
